Clinical relevance of HER-2/neu expression in germ-cell testicular tumors

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. Patients and Methods: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical method (IHC) (HercepTest) and Fluorescence in Situ Hybridization (FISH). Results: HER-2/neu overexpression was detected in 14 (24%) out of 59 specimens. With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). A statistically significant correlation (p=0.0004) can be established between HER-2/neu status and clinical stage of the disease. Similarly, a significant correlation was observed between HER-2/neu overexpression and clinical outcome (p=0.0077). None of the specimens had definite HER-2/neu gene amplification. Conclusion: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. Further studies are needed to evaluate the exact background of HER-2/neu overexpression in germ-cell tumors and the role of anti-HER-2/neu antibodies in the treatment regimens for this malignancy.

Original languageEnglish
Pages (from-to)2219-2224
Number of pages6
JournalAnticancer Research
Volume24
Issue number4
Publication statusPublished - Jul 2004

Fingerprint

erbB-2 Genes
Germ Cell and Embryonal Neoplasms
Neoplasms
Choriocarcinoma
Gene Amplification
Teratoma
Fluorescence In Situ Hybridization
Antibodies
Testicular Germ Cell Tumor
Therapeutics
Testicular Teratoma

Keywords

  • FISH
  • Germ-cell testicular tumors
  • HER-2/neu

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. / Mándoky, László; Géczi, L.; Bodrogi, I.; Tóth, J.; Csuka, O.; Kásler, M.; Bak, M.

In: Anticancer Research, Vol. 24, No. 4, 07.2004, p. 2219-2224.

Research output: Contribution to journalArticle

@article{d729983095144b8da7e3999943a355f8,
title = "Clinical relevance of HER-2/neu expression in germ-cell testicular tumors",
abstract = "Background: Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. Patients and Methods: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical method (IHC) (HercepTest) and Fluorescence in Situ Hybridization (FISH). Results: HER-2/neu overexpression was detected in 14 (24{\%}) out of 59 specimens. With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). A statistically significant correlation (p=0.0004) can be established between HER-2/neu status and clinical stage of the disease. Similarly, a significant correlation was observed between HER-2/neu overexpression and clinical outcome (p=0.0077). None of the specimens had definite HER-2/neu gene amplification. Conclusion: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. Further studies are needed to evaluate the exact background of HER-2/neu overexpression in germ-cell tumors and the role of anti-HER-2/neu antibodies in the treatment regimens for this malignancy.",
keywords = "FISH, Germ-cell testicular tumors, HER-2/neu",
author = "L{\'a}szl{\'o} M{\'a}ndoky and L. G{\'e}czi and I. Bodrogi and J. T{\'o}th and O. Csuka and M. K{\'a}sler and M. Bak",
year = "2004",
month = "7",
language = "English",
volume = "24",
pages = "2219--2224",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Clinical relevance of HER-2/neu expression in germ-cell testicular tumors

AU - Mándoky, László

AU - Géczi, L.

AU - Bodrogi, I.

AU - Tóth, J.

AU - Csuka, O.

AU - Kásler, M.

AU - Bak, M.

PY - 2004/7

Y1 - 2004/7

N2 - Background: Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. Patients and Methods: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical method (IHC) (HercepTest) and Fluorescence in Situ Hybridization (FISH). Results: HER-2/neu overexpression was detected in 14 (24%) out of 59 specimens. With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). A statistically significant correlation (p=0.0004) can be established between HER-2/neu status and clinical stage of the disease. Similarly, a significant correlation was observed between HER-2/neu overexpression and clinical outcome (p=0.0077). None of the specimens had definite HER-2/neu gene amplification. Conclusion: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. Further studies are needed to evaluate the exact background of HER-2/neu overexpression in germ-cell tumors and the role of anti-HER-2/neu antibodies in the treatment regimens for this malignancy.

AB - Background: Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. Patients and Methods: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical method (IHC) (HercepTest) and Fluorescence in Situ Hybridization (FISH). Results: HER-2/neu overexpression was detected in 14 (24%) out of 59 specimens. With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). A statistically significant correlation (p=0.0004) can be established between HER-2/neu status and clinical stage of the disease. Similarly, a significant correlation was observed between HER-2/neu overexpression and clinical outcome (p=0.0077). None of the specimens had definite HER-2/neu gene amplification. Conclusion: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. Further studies are needed to evaluate the exact background of HER-2/neu overexpression in germ-cell tumors and the role of anti-HER-2/neu antibodies in the treatment regimens for this malignancy.

KW - FISH

KW - Germ-cell testicular tumors

KW - HER-2/neu

UR - http://www.scopus.com/inward/record.url?scp=4444281358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444281358&partnerID=8YFLogxK

M3 - Article

C2 - 15330164

AN - SCOPUS:4444281358

VL - 24

SP - 2219

EP - 2224

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -